COVID-19: GP Alert (25 May 2021)
May 25, 2021
Members of the general public aged 40 - 49 can now register their interest to receive a COVID-19 Pfizer vaccine
Registrations to receive the vaccine can be made online.
Queensland Health will contact patients once appointments become available for which they are eligible.
Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca
The Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) have released a joint statement (enclosed) on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of the COVID-19 Vaccine AstraZeneca.
- The risk of TTS is not likely to be increased in people with the following conditions, and people in these groups can receive COVID-19 Vaccine AstraZeneca:
- History of blood clots in typical sites
- Increased clotting tendency that is not immune mediated
- Family history of blood clots
- History of ischaemic heart disease or stroke
- Current or past thrombocytopenia (low platelet count)
- Those receiving anticoagulation therapy.
- The list of conditions for which Comirnaty (Pfizer) is the preferred vaccine has been expanded to also include:
- Past history of idiopathic splanchnic (mesenteric, portal, splenic) vein thrombosis.
- Antiphospholipid syndrome with thrombosis.
- TTS can be treated effectively. Guidance on the identification and management of TTS is available from the Thrombosis and Haemostasis Society of Australia and New Zealand.
Click here to read the full letter provided by Professor Paul Kelly, Chief Medical Officer, for the Australian Government Department of Health.
Click here to read the TAGI and THANZ joint statement
Click here to view some talking points for GPs to assist with addressing hesitancy on AstraZeneca
UPDATED - CDNA guidelines
Version 4.4 of the Communicable Diseases Network of Australia (CDNA) Coronaivrus guidelines was released last week. Updates include: inclusion of new appendix (Outbreak investigation and management) and revisions to: Summary, The Disease, Case definition, Testing, Case Management, Release from Isolation, Management of contacts, High-risk settings.
The latest version can be found online.
NEW – Cases of community transmission in Melbourne
Victoria Health yesterday confirmed four community acquired cases of COVID-19 in Melbourne’s northern suburbs – two men, a woman, and a child from the same family. A fifth case was announced this morning (close contact of a confirmed case) and will be reported in tomorrow’s figures. A list of exposure sites has been published, with more sites expected to be added to the list.
REMINDER – Reporting Adverse Events Following Immunisation (AEFI)
Clinicians are reminded of their obligation under the Public Health Act 2005 to report serious, unexpected or uncommon AEFIs, including following a COVID-19 vaccine.
Reports can be made via the COVID-19 Adverse Event Following Immunisation portal available here.
Electronic COVID-19 AEFI Templates are now available for Best Practice and Medical Director software packages. They will help improve the efficiency of reporting as they auto-populate some information. Our PHN will be sharing additional information about these templates with you soon.
May stakeholder pack released with COVID-19 vaccine resources for multicultural audiences
The Department of Health has release a pack that contains in-language communication resources and information about the COVID-19 vaccine rollout, the AstraZeneca vaccine, vaccine eligibility and vaccine safety. Click on the links in the stakeholder pack to access translated COVID-19 vaccines information. Resources include posters, fact sheets, audio files, and social media content.
Click here to view the pack